摘要
目的探讨自由基清除剂依达拉奉治疗进展性缺血性脑卒中的临床效果。方法125例进展性缺血性脑卒中患者随机分为治疗组和对照组。治疗组65例,对照组60例。治疗组在常规治疗方法(阿司匹林、尼莫地平、胞二磷胆碱)的基础上加用依达拉奉注射液30mg静脉滴注,bid,而对照组仅用常规方法治疗。两组分别在7d、14d、21d进行脑卒中临床神经功能缺损程度评分(NDS)疗效评定以及Barthel指数(BI)评价神经功能恢复状况。结果治疗组总有效率7d(69.23%),14d(90.77%),21d(93.86%),而对照组总有效率7d(40.0%),14d(63.33%),21d(73.33%)。两组间有显著性差异。(P<0.05)。结论依达拉奉治疗进展性缺血性脑卒中安全性高,疗效显著。
Objective AIM To explore the effect of Edaravone on treatment progressive stroke, Methods 125 patients with progressive stroke were randomly assigned to therapy group （n=65） and control group（n=60）. Therapy group took as basic treatment （Aspirin, nimodipine, CDP-C）, meanwhile Edaravone was infused at a dose of 30mg, twice a day, for 14 days, Control group were similar to those of Edaravone group except for Edaravone, At 7th, 14th, 21th day after treatment, the Neurological Deficits Scale （NDS） and Barthel Index （B1） were used to evaluate the recovery of neurological functions, Results At 7th, 14th, and 21th day, the increase rate of the all efficiency rate was evaluated. There were significant difference between Edaravone group （69.23%, 90.77%, 93.86%） and control group （40,00%, 63.33%, 73.33%） （p〈0.05）. Conclusions Edaravone is a new effective and safe neuroprotective agent for treating progressive stroke.
出处
《海南医学》
CAS
2007年第4期1-2,共2页
Hainan Medical Journal
